Global CGT CDMO 麻豆原创 Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030

Publication ID:

PB506246550

Publication Date:

June 26, 2024

Pages:

148

Publisher:

MRRPB5

Countries:

Global [1]

USD 5,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

CGT CDMO is a contract service provider specializing in cell and gene therapy development and manufacturing. These organizations focus on supporting product development in the field of cell and gene therapies by pharmaceutical companies, biotechnology companies and research institutions.
The global market for CGT CDMO was estimated to be worth US$ 3947.8 million in 2023 and is forecast to a readjusted size of US$ 16970 million by 2030 with a CAGR of 24.1% during the forecast period 2024-2030.
Global key players of CGT CDMO include Catalent, Lonza and Thermo Fisher, etc. The top three players hold a share over 60%. North America is the largest market, has a share about 50%. In terms of product type, Immune Cells is the largest segment, occupied for a share of about 47%, and in terms of application, Pharmaceutical and Biotechnology Companies has a share about 82 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CGT CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding CGT CDMO.
The CGT CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CGT CDMO market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CGT CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
麻豆原创 Segmentation
By Company
Catalent
Lonza
Thermo Fisher
ACG Biologics
WuXi AppTec
Charles River
Oxford Biomedica (OXB)
Novartis
OBiO
GenScript
Pharmaron
Porton
Segment by Type
Immune Cells
Stem Cells
Viral Vectors
Plasmid DNA
Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of CGT CDMO in global and regional level.
Chapter 3: Detailed analysis of CGT CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CGT CDMO revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Study Coverage
1.1 CGT CDMO Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global CGT CDMO 麻豆原创 Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Immune Cells
1.2.3 Stem Cells
1.2.4 Viral Vectors
1.2.5 Plasmid DNA
1.3 麻豆原创 by Application
1.3.1 Global CGT CDMO 麻豆原创 Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research and Academic Institutions
1.3.4 Hospital
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global CGT CDMO 麻豆原创 Size Estimates and Forecasts
2.2 CGT CDMO 麻豆原创 Size by Region: 2023 Versus 2030
2.2.1 Global CGT CDMO Revenue by Region: 2019-2024
2.2.2 Global CGT CDMO Revenue Forecast by Region (2025-2030)
2.2.3 Global CGT CDMO Revenue 麻豆原创 Share by Region (2019-2030)
3 Global CGT CDMO by Company
3.1 Global CGT CDMO Revenue by Company (2019-2024)
3.2 Global CGT CDMO Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key CGT CDMO Companies around the World: Ranking by Revenue
3.3.2 Global CGT CDMO 麻豆原创 Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global CGT CDMO 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global CGT CDMO Companies Headquarters & Product Type
3.4.1 CGT CDMO Companies Headquarters
3.4.2 Global CGT CDMO Companies Product & Service
3.4.3 Date of International Companies Enter into CGT CDMO 麻豆原创
3.5 Global CGT CDMO Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Catalent
4.1.1 Catalent Company Information
4.1.2 Catalent Description, Business Overview
4.1.3 Catalent CGT CDMO Products Offered
4.1.4 Catalent CGT CDMO Revenue and Gross Margin (2019-2024)
4.1.5 Catalent CGT CDMO Revenue by Product in 2023
4.1.6 Catalent CGT CDMO Revenue by Application in 2023
4.1.7 Catalent CGT CDMO Revenue by Geographic Area in 2023
4.1.8 Catalent Recent Developments
4.2 Lonza
4.2.1 Lonza Company Information
4.2.2 Lonza Description, Business Overview
4.2.3 Lonza CGT CDMO Products Offered
4.2.4 Lonza CGT CDMO Revenue and Gross Margin (2019-2024)
4.2.5 Lonza CGT CDMO Revenue by Product in 2023
4.2.6 Lonza CGT CDMO Revenue by Application in 2023
4.2.7 Lonza CGT CDMO Revenue by Geographic Area in 2023
4.2.8 Lonza Recent Developments
4.3 Thermo Fisher
4.3.1 Thermo Fisher Company Information
4.3.2 Thermo Fisher Description, Business Overview
4.3.3 Thermo Fisher CGT CDMO Products Offered
4.3.4 Thermo Fisher CGT CDMO Revenue and Gross Margin (2019-2024)
4.3.5 Thermo Fisher CGT CDMO Revenue by Product in 2023
4.3.6 Thermo Fisher CGT CDMO Revenue by Application in 2023
4.3.7 Thermo Fisher CGT CDMO Revenue by Geographic Area in 2023
4.3.8 Thermo Fisher Recent Developments
4.4 ACG Biologics
4.4.1 ACG Biologics Company Information
4.4.2 ACG Biologics Description, Business Overview
4.4.3 ACG Biologics CGT CDMO Products Offered
4.4.4 ACG Biologics CGT CDMO Revenue and Gross Margin (2019-2024)
4.4.5 ACG Biologics CGT CDMO Revenue by Product in 2023
4.4.6 ACG Biologics CGT CDMO Revenue by Application in 2023
4.4.7 ACG Biologics CGT CDMO Revenue by Geographic Area in 2023
4.4.8 ACG Biologics Recent Developments
4.5 WuXi AppTec
4.5.1 WuXi AppTec Company Information
4.5.2 WuXi AppTec Description, Business Overview
4.5.3 WuXi AppTec CGT CDMO Products Offered
4.5.4 WuXi AppTec CGT CDMO Revenue and Gross Margin (2019-2024)
4.5.5 WuXi AppTec CGT CDMO Revenue by Product in 2023
4.5.6 WuXi AppTec CGT CDMO Revenue by Application in 2023
4.5.7 WuXi AppTec CGT CDMO Revenue by Geographic Area in 2023
4.5.8 WuXi AppTec Recent Developments
4.6 Charles River
4.6.1 Charles River Company Information
4.6.2 Charles River Description, Business Overview
4.6.3 Charles River CGT CDMO Products Offered
4.6.4 Charles River CGT CDMO Revenue and Gross Margin (2019-2024)
4.6.5 Charles River CGT CDMO Revenue by Product in 2023
4.6.6 Charles River CGT CDMO Revenue by Application in 2023
4.6.7 Charles River CGT CDMO Revenue by Geographic Area in 2023
4.6.8 Charles River Recent Development
4.7 Oxford Biomedica (OXB)
4.7.1 Oxford Biomedica (OXB) Company Information
4.7.2 Oxford Biomedica (OXB) Description, Business Overview
4.7.3 Oxford Biomedica (OXB) CGT CDMO Products Offered
4.7.4 Oxford Biomedica (OXB) CGT CDMO Revenue and Gross Margin (2019-2024)
4.7.5 Oxford Biomedica (OXB) CGT CDMO Revenue by Product in 2023
4.7.6 Oxford Biomedica (OXB) CGT CDMO Revenue by Application in 2023
4.7.7 Oxford Biomedica (OXB) CGT CDMO Revenue by Geographic Area in 2023
4.7.8 Oxford Biomedica (OXB) Recent Development
4.8 Novartis
4.8.1 Novartis Company Information
4.8.2 Novartis Description, Business Overview
4.8.3 Novartis CGT CDMO Products Offered
4.8.4 Novartis CGT CDMO Revenue and Gross Margin (2019-2024)
4.8.5 Novartis CGT CDMO Revenue by Product in 2023
4.8.6 Novartis CGT CDMO Revenue by Application in 2023
4.8.7 Novartis CGT CDMO Revenue by Geographic Area in 2023
4.8.8 Novartis Recent Development
4.9 OBiO
4.9.1 OBiO Company Information
4.9.2 OBiO Description, Business Overview
4.9.3 OBiO CGT CDMO Products Offered
4.9.4 OBiO CGT CDMO Revenue and Gross Margin (2019-2024)
4.9.5 OBiO CGT CDMO Revenue by Product in 2023
4.9.6 OBiO CGT CDMO Revenue by Application in 2023
4.9.7 OBiO CGT CDMO Revenue by Geographic Area in 2023
4.9.8 OBiO Recent Development
4.10 GenScript
4.10.1 GenScript Company Information
4.10.2 GenScript Description, Business Overview
4.10.3 GenScript CGT CDMO Products Offered
4.10.4 GenScript CGT CDMO Revenue and Gross Margin (2019-2024)
4.10.5 GenScript CGT CDMO Revenue by Product in 2023
4.10.6 GenScript CGT CDMO Revenue by Application in 2023
4.10.7 GenScript CGT CDMO Revenue by Geographic Area in 2023
4.10.8 GenScript Recent Development
4.11 Pharmaron
4.11.1 Pharmaron Company Information
4.11.2 Pharmaron Description, Business Overview
4.11.3 Pharmaron CGT CDMO Products Offered
4.11.4 Pharmaron CGT CDMO Revenue and Gross Margin (2019-2024)
4.11.5 Pharmaron CGT CDMO Revenue by Product in 2023
4.11.6 Pharmaron CGT CDMO Revenue by Application in 2023
4.11.7 Pharmaron CGT CDMO Revenue by Geographic Area in 2023
4.11.8 Pharmaron Recent Development
4.12 Porton
4.12.1 Porton Company Information
4.12.2 Porton Description, Business Overview
4.12.3 Porton CGT CDMO Products Offered
4.12.4 Porton CGT CDMO Revenue and Gross Margin (2019-2024)
4.12.5 Porton CGT CDMO Revenue by Product in 2023
4.12.6 Porton CGT CDMO Revenue by Application in 2023
4.12.7 Porton CGT CDMO Revenue by Geographic Area in 2023
4.12.8 Porton Recent Development
5 Breakdown Data by Type
5.1 Global CGT CDMO Revenue by Type (2019-2024)
5.2 Global CGT CDMO Revenue Forecast by Type (2025-2030)
5.3 CGT CDMO Revenue 麻豆原创 Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global CGT CDMO Revenue by Application (2019-2024)
6.2 Global CGT CDMO Revenue Forecast by Application (2025-2030)
6.3 CGT CDMO Revenue 麻豆原创 Share by Application (2019-2030)
7 North America
7.1 North America CGT CDMO 麻豆原创 Size YoY Growth 2019-2030
7.2 North America CGT CDMO 麻豆原创 Facts & Figures by Country (2019-2030)
7.3 North America CGT CDMO Revenue by Type (2019-2024)
7.4 North America CGT CDMO Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific CGT CDMO 麻豆原创 Size YoY Growth 2019-2030
8.2 Asia-Pacific CGT CDMO 麻豆原创 Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific CGT CDMO Revenue by Type (2019-2024)
8.4 Asia-Pacific CGT CDMO Revenue by Application (2019-2024)
9 Europe
9.1 Europe CGT CDMO 麻豆原创 Size YoY Growth 2019-2030
9.2 Europe CGT CDMO 麻豆原创 Facts & Figures by Country (2019-2030)
9.3 Europe CGT CDMO Revenue by Type (2019-2024)
9.4 Europe CGT CDMO Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America CGT CDMO 麻豆原创 Size YoY Growth 2019-2030
10.2 Latin America CGT CDMO 麻豆原创 Facts & Figures by Country (2019-2030)
10.3 Latin America CGT CDMO Revenue by Type (2019-2024)
10.4 Latin America CGT CDMO Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa CGT CDMO 麻豆原创 Size YoY Growth 2019-2030
11.2 Middle East and Africa CGT CDMO 麻豆原创 Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa CGT CDMO Revenue by Type (2019-2024)
11.4 Middle East and Africa CGT CDMO Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 CGT CDMO Supply Chain Analysis
12.2 CGT CDMO Key Raw Materials and Upstream Suppliers
12.3 CGT CDMO Clients Analysis
12.4 CGT CDMO Sales Channel and Sales Model Analysis
12.4.1 CGT CDMO Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 CGT CDMO Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 CGT CDMO Distributors
13 麻豆原创 Dynamics
13.1 CGT CDMO Industry Trends
13.2 CGT CDMO 麻豆原创 Drivers
13.3 CGT CDMO 麻豆原创 Challenges
13.4 CGT CDMO 麻豆原创 Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Companies Mentioned:

Catalent
Lonza
Thermo Fisher
ACG Biologics
WuXi AppTec
Charles River
Oxford Biomedica (OXB)
Novartis
OBiO
GenScript
Pharmaron
Porton

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.